Skip to main content

Articles

Page 22 of 62

  1. We investigated whether glycemic control affects the relation between endothelial dysfunction and coronary artery disease in patients with type 2 diabetes mellitus (T2DM).

    Authors: Shuai Chen, Ying Shen, Yong-Hua Liu, Yang Dai, Zhi-Ming Wu, Xiao-Qun Wang, Chen-Die Yang, Le-Ying Li, Jing-Meng Liu, Li-Ping Zhang, Wei-Feng Shen, Ri Ji, Lin Lu and Feng-Hua Ding
    Citation: Cardiovascular Diabetology 2021 20:64
    Content type: Original investigation Published on:

  2. Screening for coronary artery disease (CAD) remains broadly performed in patients with type 2 diabetes (T2DM), although the lack of evidence. We conduct a real-world evidence (RWE) study to assess the risk of ...

    Authors: Kamel Mohammedi, Nathalie Préaubert, Tanguy Cariou, Vincent Rigalleau, Ninon Foussard, Laurent Piazza, Céline Bairras-Martin, Thierry Couffinhal, Julien Bezin and Antoine Benard
    Citation: Cardiovascular Diabetology 2021 20:63
    Content type: Study protocol Published on:

  3. Type 1 diabetes mellitus (T1DM) is associated with an increased risk for cardiovascular disease (CVD) related morbidity and premature mortality. Regular physical activity plays an important role in the primary...

    Authors: Nana Wu, Shannon S. D. Bredin, Veronica K. Jamnik, Michael S. Koehle, Yanfei Guan, Erin M. Shellington, Yongfeng Li, Jun Li and Darren E. R. Warburton
    Citation: Cardiovascular Diabetology 2021 20:62
    Content type: Original investigation Published on:

  4. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Pratibha Singh, Isabel Goncalves, Christofer Tengryd, Mihaela Nitulescu, Ana F. Persson, Fong To, Eva Bengtsson, Petr Volkov, Marju Orho-Melander, Jan Nilsson and Andreas Edsfeldt
    Citation: Cardiovascular Diabetology 2021 20:61
    Content type: Correction Published on:

    The original article was published in Cardiovascular Diabetology 2020 19:214

  5. Women with type 2 diabetes (T2DM) have a higher excess risk for cardiovascular disease (CVD) than their male counterparts. However, whether the risk for CVD is higher in prediabetic women than men is still deb...

    Authors: Elena Succurro, Sofia Miceli, Teresa Vanessa Fiorentino, Angela Sciacqua, Maria Perticone, Francesco Andreozzi and Giorgio Sesti
    Citation: Cardiovascular Diabetology 2021 20:60
    Content type: Original investigation Published on:

  6. The European Society of Cardiology (ESC) recently defined cardiovascular risk classes for subjects with diabetes. Aim of this study was to explore the distribution of subjects with type 2 diabetes (T2D) by car...

    Authors: Basilio Pintaudi, Alessia Scatena, Gabriella Piscitelli, Vera Frison, Salvatore Corrao, Valeria Manicardi, Giusi Graziano, Maria Chiara Rossi, Marco Gallo, Domenico Mannino, Paolo Di Bartolo and Antonio Nicolucci
    Citation: Cardiovascular Diabetology 2021 20:59
    Content type: Original investigation Published on:

  7. Adults who have experienced multiple cardiovascular disease (CVD) events have a very high risk for additional events. Diabetes and chronic kidney disease (CKD) are each associated with an increased risk for re...

    Authors: Demetria Hubbard, Lisandro D. Colantonio, Robert S. Rosenson, Todd M. Brown, Elizabeth A. Jackson, Lei Huang, Kate K. Orroth, Stephanie Reading, Mark Woodward, Vera Bittner, Orlando M. Gutierrez, Monika M. Safford, Michael E. Farkouh and Paul Muntner
    Citation: Cardiovascular Diabetology 2021 20:58
    Content type: Original investigation Published on:

  8. Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that has demonstrated cardiovascular and renal protection in patients with type 2 diabetes (T2D). We hypothesized that empaglifozin (EMPA) co...

    Authors: B. Gaborit, P. Ancel, A. E. Abdullah, F. Maurice, I. Abdesselam, A. Calen, A. Soghomonian, M. Houssays, I. Varlet, M. Eisinger, A. Lasbleiz, F. Peiretti, C. E. Bornet, Y. Lefur, L. Pini, S. Rapacchi…
    Citation: Cardiovascular Diabetology 2021 20:57
    Content type: Original investigation Published on:

  9. Impaired fasting glucose (IFG) is a prevalent and potentially reversible intermediate stage leading to type 2 diabetes that increases risk for cardiometabolic complications. The identification of clinical and ...

    Authors: Magdalena del Rocío Sevilla-González, Jordi Merino, Hortensia Moreno-Macias, Rosalba Rojas-Martínez, Donají Verónica Gómez-Velasco and Alisa K. Manning
    Citation: Cardiovascular Diabetology 2021 20:56
    Content type: Original investigation Published on:

  10. The epidemic of diabetes mellitus (DM) necessitates the development of novel therapeutic and preventative strategies to attenuate complications of this debilitating disease. Diabetic cardiomyopathy (DCM) is a ...

    Authors: Daniel Jakubik, Alex Fitas, Ceren Eyileten, Joanna Jarosz-Popek, Anna Nowak, Pamela Czajka, Zofia Wicik, Harald Sourij, Jolanta M. Siller-Matula, Salvatore De Rosa and Marek Postula
    Citation: Cardiovascular Diabetology 2021 20:55
    Content type: Review Published on:

  11. The prognostic importance of non-traditional risk factors for peripheral artery disease (PAD) development/progression is scarcely studied in diabetes. We investigated if carotid intima-media thickness (CIMT) a...

    Authors: Claudia R. L. Cardoso, Juliana V. Melo, Thainá R. M. Santos, Nathalie C. Leite and Gil F. Salles
    Citation: Cardiovascular Diabetology 2021 20:54
    Content type: Original investigation Published on:

  12. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Judith van Haare, M. Eline Kooi, Jurgen W. G. E. van Teeffelen, Hans Vink, Jos Slenter, Hanneke Cobelens, Gustav J. Strijkers, Dennis Koehn, Mark J. Post and Marc van Bilsen
    Citation: Cardiovascular Diabetology 2021 20:53
    Content type: Correction Published on:

    The original article was published in Cardiovascular Diabetology 2017 16:47

  13. Diabetes increases a patient’s risk of developing atrial fibrillation by 49%. Patients with nonvalvular atrial fibrillation are at a fivefold increased risk of stroke and die more frequently from vascular caus...

    Authors: Craig I. Coleman, Olivia S. Costa, Christopher W. Brescia, Burcu Vardar, Khaled Abdelgawwad and Nitesh Sood
    Citation: Cardiovascular Diabetology 2021 20:52
    Content type: Original investigation Published on:

  14. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Judith van Haare, M. Eline Kooi, Hans Vink, Mark J. Post, Jurgen W. G. E. van Teeffelen, Jos Slenter, Chantal Munts, Hanneke Cobelens, Gustav J. Strijkers, Dennis Koehn and Marc van Bilsen
    Citation: Cardiovascular Diabetology 2021 20:51
    Content type: Correction Published on:

    The original article was published in Cardiovascular Diabetology 2015 14:150

  15. Acetylcholine (ACh) plays a crucial role in the function of the heart. Recent evidence suggests that cardiomyocytes possess a non-neuronal cholinergic system (NNCS) that comprises of choline acetyltransferase ...

    Authors: Eng Leng Saw, James T. Pearson, Daryl O. Schwenke, Pujika Emani Munasinghe, Hirotsugu Tsuchimochi, Shruti Rawal, Sean Coffey, Philip Davis, Richard Bunton, Isabelle Van Hout, Yuko Kai, Michael J. A. Williams, Yoshihiko Kakinuma, Martin Fronius and Rajesh Katare
    Citation: Cardiovascular Diabetology 2021 20:50
    Content type: Original investigation Published on:

  16. Soluble suppression of tumorigenesis-2 (sST2) is implicated in myocardial overload and has long been recognized as an inflammatory marker related to heart failure and acute coronary syndrome, but data on the p...

    Authors: Man Li, Lei Duan, Yulun Cai, Benchuan Hao, Jianqiao Chen, Huiying Li and Hongbin Liu
    Citation: Cardiovascular Diabetology 2021 20:49
    Content type: Original investigation Published on:

  17. Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome, with several underlying etiologic and pathophysiologic factors. The presence of diabetes might identify an important phenotyp...

    Authors: Sibille Lejeune, Clotilde Roy, Alisson Slimani, Agnès Pasquet, David Vancraeynest, Jean-Louis Vanoverschelde, Bernhard L. Gerber, Christophe Beauloye and Anne-Catherine Pouleur
    Citation: Cardiovascular Diabetology 2021 20:48
    Content type: Original investigation Published on:

  18. Patients with type 2 diabetes mellitus (T2DM) are at high risk of cardiovascular mortality, but the mechanisms behind this remain unclear. Prothrombotic fibrin clot properties have been shown in T2DM and cardi...

    Authors: Agata Hanna Bryk, Małgorzata Konieczyńska, Maciej Polak, Dariusz Plicner, Maciej Bochenek and Anetta Undas
    Citation: Cardiovascular Diabetology 2021 20:47
    Content type: Original investigation Published on:

  19. Triglyceride-glucose (TyG) index was recently suggested to be a reliable surrogate marker of insulin resistance. We aim to investigate the associations between baseline and long-term TyG index with subsequent ...

    Authors: Anxin Wang, Guangyao Wang, Qian Liu, Yingting Zuo, Shuohua Chen, Boni Tao, Xue Tian, Penglian Wang, Xia Meng, Shouling Wu, Yongjun Wang and Yilong Wang
    Citation: Cardiovascular Diabetology 2021 20:46
    Content type: Original investigation Published on:

  21. Endothelial progenitor cells (EPCs) has been shown to be dysfunctional in both type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) leading to poor regeneration of endothelium and renal perfusion. ...

    Authors: Seshagiri Rao Nandula, Nabanita Kundu, Hassan B. Awal, Beda Brichacek, Mona Fakhri, Nikhila Aimalla, Adrian Elzarki, Richard L. Amdur and Sabyasachi Sen
    Citation: Cardiovascular Diabetology 2021 20:44
    Content type: Original investigation Published on:

  22. Triglyceride glucose (TyG) index is considered a reliable alternative marker of insulin resistance and an independent predictor of cardiovascular (CV) outcomes. However, the prognostic value of TyG index in pa...

    Authors: Yue Zhang, Xiaosong Ding, Bing Hua, Qingbo Liu, Hui Gao, Hui Chen, Xue-Qiao Zhao, Weiping Li and Hongwei Li
    Citation: Cardiovascular Diabetology 2021 20:43
    Content type: Original investigation Published on:

  24. Clinical trials are often performed to investigate the effects of various types of cardiometabolic therapies on cardiovascular surrogate markers, including vascular function and biomarkers. This study platform...

    Authors: Atsushi Tanaka and Koichi Node
    Citation: Cardiovascular Diabetology 2021 20:41
    Content type: Commentary Published on:

  25. There are limited data on the association of diabetes mellitus (DM) and levels of glycated hemoglobin (HbA1c) with outcomes in patients with atrial fibrillation (AF).

    Authors: Andreas S. Papazoglou, Anastasios Kartas, Athanasios Samaras, Ioannis Vouloagkas, Eleni Vrana, Dimitrios V. Moysidis, Evangelos Akrivos, Georgios Kotzampasis, Amalia Baroutidou, Anastasios Papanastasiou, Evangelos Liampas, Michail Botis, Efstratios Karagiannidis, Nikolaos Stalikas, Haralambos Karvounis, Apostolos Tzikas…
    Citation: Cardiovascular Diabetology 2021 20:40
    Content type: Original investigation Published on:

  26. Sodium glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of heart failure and new data show they can prevent atrial fibrillation (AF). We examined the association between SGLT2i and AF in the Food an...

    Authors: Benedetta Maria Bonora, Emanuel Raschi, Angelo Avogaro and Gian Paolo Fadini
    Citation: Cardiovascular Diabetology 2021 20:39
    Content type: Original investigation Published on:

  27. Gender disparities in the management of dysglycaemia, defined as either impaired glucose tolerance (IGT) or type 2 diabetes (T2DM), in coronary artery disease (CAD) patients are a medical challenge. Recent dat...

    Authors: Giulia Ferrannini, Dirk De Bacquer, Pieter Vynckier, Guy De Backer, Viveca Gyberg, Kornelia Kotseva, Linda Mellbin, Anna Norhammar, Jaakko Tuomilehto, David Wood and Lars Rydén
    Citation: Cardiovascular Diabetology 2021 20:38
    Content type: Original investigation Published on:

  28. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Shaminie J. Athinarayanan, Sarah J. Hallberg, Amy L. McKenzie, Katharina Lechner, Sarah King, James P. McCarter, Jeff S. Volek, Stephen D. Phinney and Ronald M. Krauss
    Citation: Cardiovascular Diabetology 2021 20:37
    Content type: Correction Published on:

    The original article was published in Cardiovascular Diabetology 2020 19:208

  29. In this commentary, we introduce the concepts of removed and residual risks in conditioning thecardiorenal outlook of patients with type 2 diabetes (T2D). The removed cardiorenal risk represents the risk of pr...

    Authors: Dario Giugliano, Maria Ida Maiorino, Giuseppe Bellastella and Katherine Esposito
    Citation: Cardiovascular Diabetology 2021 20:36
    Content type: Commentary Published on:

  30. Epicardial adipose tissue (EAT) has anatomic and functional proximity to the heart and is considered a novel diagnostic marker and therapeutic target in cardiometabolic diseases. The aim of this study was to e...

    Authors: Emmanuel Cosson, Minh Tuan Nguyen, Imen Rezgani, Sopio Tatulashvili, Meriem Sal, Narimane Berkane, Lucie Allard, Pierre-Yves Brillet and Hélène Bihan
    Citation: Cardiovascular Diabetology 2021 20:35
    Content type: Original investigation Published on:

  31. Recently, the European Society of Cardiology (ESC) and European Association for the Society of Diabetes (EASD) introduced a new cardiovascular disease (CVD) risk stratification model to aid further treatment d...

    Authors: Suriya Prausmüller, Michael Resl, Henrike Arfsten, Georg Spinka, Raphael Wurm, Stephanie Neuhold, Philipp E. Bartko, Georg Goliasch, Guido Strunk, Noemi Pavo, Martin Clodi and Martin Hülsmann
    Citation: Cardiovascular Diabetology 2021 20:34
    Content type: Original investigation Published on:

  32. Hyperglycemia has been associated with increased inflammatory indexes and larger infarct sizes in patients with obstructive acute myocardial infarction (obs-AMI). In contrast, no studies have explored these co...

    Authors: Pasquale Paolisso, Alberto Foà, Luca Bergamaschi, Francesco Donati, Michele Fabrizio, Chiara Chiti, Francesco Angeli, Sebastiano Toniolo, Andrea Stefanizzi, Matteo Armillotta, Paola Rucci, Gianmarco Iannopollo, Gianni Casella, Cinzia Marrozzini, Nazzareno Galiè and Carmine Pizzi
    Citation: Cardiovascular Diabetology 2021 20:33
    Content type: Original investigation Published on:

  33. While the cardioprotective benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors have been established in patients with cardiovascular disease (CVD), their advantages over other anti-diabetic drugs at ...

    Authors: Shigenori Hiruma, Fumika Shigiyama, Shinji Hisatake, Sunao Mizumura, Nobuyuki Shiraga, Masaaki Hori, Takanori Ikeda, Takahisa Hirose and Naoki Kumashiro
    Citation: Cardiovascular Diabetology 2021 20:32
    Content type: Original investigation Published on:

  34. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Lei Guo, Junjie Wang, Huaiyu Ding, Shaoke Meng, Xiaoyan Zhang, Haichen Lv, Lei Zhong, Jian Wu, Jiaying Xu, Xuchen Zhou and Rongchong Huang
    Citation: Cardiovascular Diabetology 2021 20:31
    Content type: Correction Published on:

    The original article was published in Cardiovascular Diabetology 2020 19:100

  35. Metformin is a first-line drug in type 2 diabetes mellitus (T2DM) treatment, yet whether metformin may increase all-cause or cardiovascular mortality of T2DM patients remains inconclusive.

    Authors: Tian Li, Rui Providencia, Nan Mu, Yue Yin, Mai Chen, Yishi Wang, Manling Liu, Lu Yu, Chunhu Gu and Heng Ma
    Citation: Cardiovascular Diabetology 2021 20:30
    Content type: Original investigation Published on:

  36. Diabetes mellitus (DM) is highly prevalent among patients undergoing percutaneous coronary intervention (PCI) for chronic total occlusion (CTO). Therefore, the purpose of our study was to investigate the clini...

    Authors: Yong Zhu, Shuai Meng, Maolin Chen, Kesen Liu, Ruofei Jia, Hong Li, Huagang Zhu and Zening Jin
    Citation: Cardiovascular Diabetology 2021 20:29
    Content type: Original investigation Published on:

  37. Atherogenic dyslipidaemia has been implicated in the residual risk for cardiovascular morbidity and mortality, which remains despite attainment of LDL cholesterol goals especially in individuals with type 2 di...

    Authors: Emanuela Orsi, Giuseppe Penno, Anna Solini, Enzo Bonora, Cecilia Fondelli, Roberto Trevisan, Monica Vedovato, Franco Cavalot, Susanna Morano, Marco G. Baroni, Antonio Nicolucci and Giuseppe Pugliese
    Citation: Cardiovascular Diabetology 2021 20:28
    Content type: Original investigation Published on:

  38. We sought to evaluate the association of metabolic syndrome (MetS) and computed tomography (CT)-derived cardiometabolic biomarkers (non-alcoholic fatty liver disease [NAFLD] and epicardial adipose tissue [EAT]...

    Authors: Andrew Lin, Nathan D. Wong, Aryabod Razipour, Priscilla A. McElhinney, Frederic Commandeur, Sebastien J. Cadet, Heidi Gransar, Xi Chen, Stephanie Cantu, Robert J. H. Miller, Nitesh Nerlekar, Dennis T. L. Wong, Piotr J. Slomka, Alan Rozanski, Balaji K. Tamarappoo, Daniel S. Berman…
    Citation: Cardiovascular Diabetology 2021 20:27
    Content type: Original investigation Published on:

  39. The independent role of pericardial adipose tissue (PAT) as an ectopic fat associated with cardiovascular disease (CVD) remains controversial. This study aimed to determine whether PAT is associated with left ...

    Authors: Jin-Seok Kim, Seon Won Kim, Jong Seok Lee, Seung Ku Lee, Robert Abbott, Ki Yeol Lee, Hong Euy Lim, Ki-Chul Sung, Goo-Yeong Cho, Kwang Kon Koh, Sun H. Kim, Chol Shin and Seong Hwan Kim
    Citation: Cardiovascular Diabetology 2021 20:26
    Content type: Original investigation Published on:

  40. Although the benefits of sodium–glucose cotransporter 2 inhibitors (SGLT2i) on cardiovascular events have been reported in patients with type 2 diabetes mellitus (T2DM) with or without heart failure (HF), the ...

    Authors: Yi-Wen Yu, Xue-Mei Zhao, Yun-Hong Wang, Qiong Zhou, Yan Huang, Mei Zhai and Jian Zhang
    Citation: Cardiovascular Diabetology 2021 20:25
    Content type: Review Published on:

  41. There remain uncertainties regarding diabetes mellitus and the incidence of atrial fibrillation (AF), in relation to type of diabetes, and the interactions with sex and age. We investigated whether diabetes co...

    Authors: Arnaud Bisson, Alexandre Bodin, Grégoire Fauchier, Julien Herbert, Denis Angoulvant, Pierre Henri Ducluzeau, Gregory Y. H. Lip and Laurent Fauchier
    Citation: Cardiovascular Diabetology 2021 20:24
    Content type: Original investigation Published on:

  42. Diabetes patients without obstructive coronary artery disease as assessed by coronary angiography have a low risk of myocardial infarction, but their myocardial infarction risk may still be higher than the gen...

    Authors: Kevin Kris Warnakula Olesen, Morten Madsen, Christine Gyldenkerne, Pernille Gro Thrane, Troels Thim, Lisette Okkels Jensen, Hans Erik Bøtker, Henrik Toft Sørensen and Michael Maeng
    Citation: Cardiovascular Diabetology 2021 20:23
    Content type: Original investigation Published on:

  43. Insulin resistance carries increased risk of heart failure, although the pathophysiological mechanisms remain unclear. LV global longitudinal strain (LVGLS) assessed by speckle-tracking echocardiography has em...

    Authors: Kazutoshi Hirose, Koki Nakanishi, Masao Daimon, Naoko Sawada, Yuriko Yoshida, Kentaro Iwama, Yuko Yamamoto, Jumpei Ishiwata, Megumi Hirokawa, Katsuhiro Koyama, Tomoko Nakao, Hiroyuki Morita, Marco R. Di Tullio, Shunichi Homma and Issei Komuro
    Citation: Cardiovascular Diabetology 2021 20:22
    Content type: Original investigation Published on:

  44. To conduct a real-word-study-based cost-effectiveness analysis of a GLP-1 receptor agonist (GLP-1RA) versus insulin among type 2 diabetes patients requiring intensified injection therapy and a systematic revie...

    Authors: Chen-Yi Yang, Ying-Ren Chen, Huang-Tz Ou and Shihchen Kuo
    Citation: Cardiovascular Diabetology 2021 20:21
    Content type: Original investigation Published on:

  45. The metabolic syndrome (MetS) and its components are associated with the development of atrial fibrillation (AF). However, the impact of time-burden of MetS on the risk of AF is unknown. We investigated the ef...

    Authors: Hyo-Jeong Ahn, Kyung-Do Han, Eue-Keun Choi, Jin-Hyung Jung, Soonil Kwon, So-Ryoung Lee, Seil Oh and Gregory Y. H. Lip
    Citation: Cardiovascular Diabetology 2021 20:20
    Content type: Original investigation Published on:

  46. The triglyceride–glucose (TyG) index, which is a simple surrogate marker of insulin resistance, has been suggested as a contributor of cardiovascular disease. However, evidence on the effect of long-term eleva...

    Authors: Xue Tian, Yingting Zuo, Shuohua Chen, Qian Liu, Boni Tao, Shouling Wu and Anxin Wang
    Citation: Cardiovascular Diabetology 2021 20:19
    Content type: Original investigation Published on:

  47. Mortality in individuals with diabetes with severe hypoglycemia requiring ambulance services intervention is high and it is unclear whether this is modifiable. Our aim was to characterise this high-risk group ...

    Authors: Sam M. Pearson, Beverley Whittam, Kavita Kulavarasalingam, Amelia Mitchell-Gears, Cathyrn James and Ramzi A. Ajjan
    Citation: Cardiovascular Diabetology 2021 20:18
    Content type: Original investigation Published on:

  48. Hospitalization for major diabetes complications, including myocardial infarction, stroke, lower-extremity amputation, and end-stage kidney disease, is on the rise and represents a great health burden for pati...

    Authors: Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, Paola Caruso and Katherine Esposito
    Citation: Cardiovascular Diabetology 2021 20:17
    Content type: Review Published on:

  49. Patients with diabetes and triple-vessel disease (TVD) are associated with a high risk of events. The choice of treatment strategies remains a subject of discussion. In the real-world, we aim to compare the ou...

    Authors: Xueyan Zhao, Lianjun Xu, Lin Jiang, Jian Tian, Yin Zhang, Dong Wang, Kai Sun, Bo Xu, Wei Zhao, Rutai Hui, Runlin Gao, Lei Song and Jinqing Yuan
    Citation: Cardiovascular Diabetology 2021 20:16
    Content type: Original investigation Published on:

  50. Patients with diabetes and acute coronary syndrome (ACS) are at high risk for subsequent heart failure. Apabetalone is a selective inhibitor of bromodomain and extra-terminal (BET) proteins, epigenetic regulat...

    Authors: Stephen J. Nicholls, Gregory G. Schwartz, Kevin A. Buhr, Henry N. Ginsberg, Jan O. Johansson, Kamyar Kalantar-Zadeh, Ewelina Kulikowski, Peter P. Toth, Norman Wong, Michael Sweeney and Kausik K. Ray
    Citation: Cardiovascular Diabetology 2021 20:13
    Content type: Original investigation Published on:
journal logo

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Submit manuscript

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 8.5
    5-year Journal Impact Factor: 8.9
    Source Normalized Impact per Paper (SNIP): 1.855
    SCImago Journal Rank (SJR): 2.621

    Speed 2023
    Submission to first editorial decision (median days): 2
    Submission to acceptance (median days): 56

    Usage 2023
    Downloads: 2,523,778
    Altmetric mentions: 3,115

Cardiovascular Diabetology

ISSN: 1475-2840